Asked by: Lord Bird (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to address inequalities in maternal health outcomes, particularly among women from deprived or marginalised backgrounds.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises that there are stark inequalities for women and babies, and that they should receive the high-quality care they deserve, regardless of their background, location, or ethnicity.
Baroness Amos is chairing the National Independent Maternity and Neonatal Investigation which aims to identify the drivers and impact of inequalities faced by women, babies, and families from Black and Asian backgrounds, as well as deprived and marginalised groups.
The Government is committed to setting an explicit target to close the maternal mortality gap. We are ensuring that we take an evidence-based approach to determining what targets are set, and that any targets set are women and baby-centred.
NHS England’s Perinatal Equity and Anti-Discrimination Programme aims to ensure that all service users and their families receive care that is free from discrimination and racism. Local Maternity and Neonatal Systems have published Equity and Equality action plans containing evidence-based interventions to support women and families from ethnic minority backgrounds or economically deprived areas. NHS England also launched the Maternal Care Bundle that sets clear standards across all services, focused on the main causes of maternal death and harm. The Maternal Care Bundle is avaiable on the NHS.UK website. Women from Black and Asian backgrounds are more at risk of specific clinical conditions that are the leading causes of death. This bundle targets these conditions, and we expect a decline in deaths and harm.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department for Education:
To ask the Secretary of State for Education, what steps she is taking to ensure schools tackle gender-specific online harm.
Answered by Georgia Gould - Minister of State (Education)
The updated relationships, sex and health education guidance ensures that, from September 2026, schools will address gender‑based online harms including from pornography, deepfakes, sextortion and misogynistic content. It places new emphasis on challenging misogyny and supporting pupils to recognise and report harmful behaviours and to understand the impact of harmful online influencers.
In December 2025, the government published a new strategy to tackle violence against women and girls. We want to protect young people and drive forward education on healthy relationships. We will invest £11 million to pilot the best interventions in schools over the next three years.
‘Keeping children safe in education’, the statutory safeguarding guidance which schools must have regard to, has been strengthened significantly in recent years to reflect evolving online risks. Online safety is embedded throughout, making clear the importance of ensuring a whole school approach to keeping children safe both online and offline.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) diagnosis, (b) treatment and (c) ongoing care for patients with endometriosis.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government is committed to prioritising women’s health, including endometriosis diagnosis, treatment, and ongoing care. It is unacceptable that women can wait so long for an endometriosis diagnosis, and we have already taken action to address this.
The National Institute for Health and Care Excellence (NICE) updated their guideline on endometriosis in November 2024 to make firmer recommendations on referral and investigations, and this will help women receive a diagnosis and effective treatment faster.
Research has led to new treatments being made available, including the NICE approval of two pills to treat endometriosis this year, namely Relugolix and Linzagolix. Both are estimated to help approximately 1,000 women with severe endometriosis for whom other treatment options haven’t been effective.
Through the National Institute for Health and Care Research (NIHR), the Department has commissioned several studies focused on endometriosis diagnosis, treatment, and patient experience. At present, the NIHR is funding five active research awards into endometriosis totalling an investment of approximately £5.5 million. A further £2.3 million award on the effectiveness of pain management for endometriosis is due to commence in March 2026.
We are expanding the number of dedicated and protected surgical hubs, of which gynaecology procedures are a key offering.
As announced in September, we will establish an “online hospital”, NHS Online, which will give people on certain pathways the choice of getting the specialist care they need from their home. Menstrual problems that may be a sign of several conditions, including endometriosis, will be among the conditions available for referral to NHS Online from 2027.
NHS England is also updating the service specification for severe endometriosis which is due to be published in due course. This will improve the standards of care for women with severe endometriosis by ensuring specialist endometriosis services have access to the most up-to-date evidence and advice.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government which national body has formal responsibility for monitoring outcomes for placenta accreta spectrum, including missed antenatal diagnoses and maternal morbidity.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
There are currently no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta routinely in regular surveillance. However, MBRRACE-UK captures this data as part of their confidential enquiries relating to haemorrhage.
In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. Placenta accreta centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they plan to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes; and if so, over what timetable.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
There are currently no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta routinely in regular surveillance. However, MBRRACE-UK captures this data as part of their confidential enquiries relating to haemorrhage.
In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. Placenta accreta centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they plan to discuss the publication of data on maternal deaths and severe maternal morbidity specifically attributable to placenta accreta spectrum with Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. These centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.
At present, placenta accreta spectrum is not included as an indicator in NHS England maternity safety improvement programmes and dashboards. There are no plans to add this as an indicator in the future.
There are no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta spectrum routinely in regular surveillance. However, MBRRACE-UK captures this data as part of the haemorrhage confidential enquiries. There are currently no plans to discuss the publication of this data.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether there is a national audit mechanism to review cases of placenta accreta spectrum that were not diagnosed antenatally and resulted in emergency hysterectomy, major haemorrhage or fatality.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. These centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.
At present, placenta accreta spectrum is not included as an indicator in NHS England maternity safety improvement programmes and dashboards. There are no plans to add this as an indicator in the future.
There are no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta spectrum routinely in regular surveillance. However, MBRRACE-UK captures this data as part of the haemorrhage confidential enquiries. There are currently no plans to discuss the publication of this data.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether placenta accreta spectrum is included as an indicator in NHS England maternity safety improvement programmes and dashboards; and if not, whether placenta accreta spectrum will be added as an indicator.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2020, NHS England commissioned placenta accreta networks in the United Kingdom which support local and regional screening, shared protocols, and co-ordinated referral pathways to specialist pregnancy accreta centres. These centres consist of highly experienced multidisciplinary teams with the expertise to manage this condition and improve the safety outcomes for women and babies.
At present, placenta accreta spectrum is not included as an indicator in NHS England maternity safety improvement programmes and dashboards. There are no plans to add this as an indicator in the future.
There are no plans to introduce mandatory national reporting of placenta accreta spectrum cases and outcomes. Neither Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK) nor the National Maternity and Perinatal Audit record placenta accreta spectrum routinely in regular surveillance. However, MBRRACE-UK captures this data as part of the haemorrhage confidential enquiries. There are currently no plans to discuss the publication of this data.
Asked by: Josh Babarinde (Liberal Democrat - Eastbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department has taken to help ensure that people from (a) ethnic minority and (b) low socio-economic backgrounds have adequate access to endometriosis diagnosis services.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government acknowledges the challenges faced by women with endometriosis and the impact it has on their lives, their relationships, and their participation in education and the workforce.
The 10-Year Health Plan described our reimagined National Health Service, which will be designed to tackle inequalities in both access and outcomes, as well as to give everyone, no matter who they are or where they come from, the means to engage with the NHS on their own terms.
We are committed to improving the diagnosis, treatment, and ongoing care for gynaecological conditions, including endometriosis for all women, and we have already taken action to address this.
£25 million has been invested in women’s health hubs to improve care for common gynaecological and urogynaecological conditions, with care for endometriosis outlined as a core service within the women’s health hubs. The women’s health hubs aim to address gaps in provision and long waiting times, specifically for those from low socio-economic background or those who are from minority ethnic backgrounds.
The National Institute for Health and Care Excellence has updated their guidelines on endometriosis in November 2024, with two new treatments having been approved, and we are investing £5.6 million into research to support our efforts in gynaecology and are taking action to cut gynaecology waiting lists through our Elective Reform Plan.
Asked by: Josh Babarinde (Liberal Democrat - Eastbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department has taken to help ensure the guidance on endometriosis published by National Institute for Health and Care Excellence is effectively implemented.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government acknowledges the challenges faced by women with endometriosis and the impact it has on their lives, their relationships, and their participation in education and the workforce.
We are committed to improving the diagnosis, treatment, and ongoing care for gynaecological conditions including endometriosis, and we have already taken action to address this.
In November 2024, the National Institute for Health and Care Excellence (NICE) updated its guideline on the diagnosis and management of endometriosis. The guideline, Endometriosis: diagnosis and management, aims to raise awareness of endometriosis symptoms, and to provide clear advice on referral, diagnosis, and the range of treatments available.
NICE will be working with National Health Service systems to ensure adoption of this best practice endometriosis care, including access to approved medicines.
NHS England encourages adherence to guidance publications by NICE. However, professionals and practitioners are expected to exercise their judgement when taking NICE guidelines into account, alongside the individual needs, preferences, and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families, and carers or guardian.